Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash & Equivalents (2016 - 2025)

Arcadia Biosciences' Cash & Equivalents history spans 12 years, with the latest figure at $259000.0 for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 93.89% year-over-year to $259000.0; the TTM value through Dec 2025 reached $259000.0, down 93.89%, while the annual FY2025 figure was $259000.0, 93.89% down from the prior year.
  • Cash & Equivalents reached $259000.0 in Q4 2025 per RKDA's latest filing, down from $1.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $44.0 million in Q2 2021 to a low of $259000.0 in Q4 2025.
  • Average Cash & Equivalents over 5 years is $15.3 million, with a median of $12.0 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 340.23% in 2021, then plummeted 93.89% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $28.7 million in 2021, then fell by 28.03% to $20.6 million in 2022, then crashed by 68.43% to $6.5 million in 2023, then crashed by 34.92% to $4.2 million in 2024, then tumbled by 93.89% to $259000.0 in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Cash & Equivalents are $259000.0 (Q4 2025), $1.1 million (Q3 2025), and $1.4 million (Q2 2025).